 Outcome measures in trials for ambulant DMD patients are the 6MWT, NSAA and 4SC.  Limitations related to patient motivation during the assessment for these measures.  The wearable device measurement intends to overcome such limitations.  SV95C measured is an acceptable secondary endpoint in pivotal or exploratory trials reliably and continuously in a home environment with a wearable device.
Amongst functional measures, regulators recognise that ambulation is an important milestone in DMD patients, and the 6-minute walk test (6MWT) 3, 4 has been used in a modified version as an endpoint in pivotal DMD clinical trials. Known limitations with the 6MWT include: a learning effect, high inter-and intra-person variability, the impact of age and motivation, and the applicability to ambulant patients only. Regulators currently recommend that if the 6MWT is selected as the primary endpoint, results on efficacy should be supported by secondary clinical outcomes such as timed-function tests, pure motor function tests, muscle strength, disability, activities of daily living or cardio-pulmonary function testing.
One way of seeking regulatory endorsement of a potential new endpoint is the European Medicines Agency's qualification procedure for novel methods. Teams of regulators assess whether a novel method could be used in trials for regulatory decision making and what weight could be given to it, as in the case for SV95C. corresponds to the real distance as measured manually (validity study).
2. Measurement of the variability of gait variables and studying the influence of poor compliance to generate recommended minimal use.
3. Cross validating these measures with 6MWT and NSAA.
4. Studying the sensitivity to change over a 6 month and a 1 year period in patients older than 6 years old and walking less than 450 m in 6MWT.
Discussion
When reviewing the regulatory utility of SV95C, regulators considered data on accuracy, reliability, sensitivity to change and clinical relevance. The data revealed a high rate of accuracy for measurements of stride length and velocity compared to an optical motion capture system, and that the stride parameters measured with the system are consistent with the 6MWT distance taking into account the "turn" distance, which is not counted by the physiotherapist.
In terms of reliability, the SV95C was calculated from a period of 180 hours of summed recorded data per individual. This period seemed to ensure low variability while keeping good compliance. Daily recording including weekends is needed for representative data. Therefore, in ambulant DMD patients, 30 day wearing periods are proposed to ensure that sufficient data are generated during a set period for almost all patients. In clinical trials one month measurement periods will be proposed at various study time points (e.g. baseline, months 3, 6, 12). Whilst compliance rates presented were quite high, the handling of missing data would need to be addressed in any study protocol, together with other measures such as training, and instructions.
A C C E P T E D M
A N U S C R I P T A correlation analysis was presented based on cross-sectional SV95C data from 45 DMD patients vs 6MWT, NSAA and 4SC. The number of patients included in the tests is low, but the data are consistent and SV95C was significantly correlated with the validated 6MWT and NSAA.
Regarding sensitivity to change, longitudinal (31 patients at 6 months and 11 patients at 12 months for SV95C vs 6MWT) changes observed for the SV95C are in line with those observed in DMD studies for 6MWT. Baseline normative data indicate that stride speed and stride length clearly discriminate between controls and DMD, especially when expressed as 95th centile.
Further research to expand normative data in comparison to the 6MWT in heathy age-matched controls is encouraged.
For the minimally clinically important difference (MCID), the Applicant used distribution methods applied 3, 6 for the 6MWT (MCID of 30m) proposing an MCID of 0.1 m/s for SV95C. To assess whether this MCID for SV95C is in the same order of magnitude as that for the 6MWT, two calculations were presented: The first was to convert the speed at this MCID directly in the A C C E P T E D M A N U S C R I P T
